Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tilarginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 known ✓ | P29475 | 4/20 | 0.45 |
| ▸ | NOS2 known ✓ | P35228 | 4/20 | 0.45 |
| ▸ | NOS3 known ✓ | P29474 | 3/20 | 0.45 |
| ▸ | OTC | P00480 | 1/20 | 0.50 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | ARG2 | P78540 | 4/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | ARG1 | P05089 | 3/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tilarginine SCHEMBL315843 | 0.98 | OTC (0.51) | OTCNOS1NOS2NOS3DDAH1 | |
| Tilarginine SCHEMBL12028766 | 0.98 | OTC (0.51) | OTCNOS1NOS2NOS3DDAH1 | |
| Tilarginine SCHEMBL6370536 | 0.98 | OTC (0.51) | OTCNOS1NOS2NOS3DDAH1 | |
| Tilarginine SCHEMBL1321022 | 0.95 | OTC (0.49) | OTCNOS1NOS2NOS3DDAH1 | |
| SCHEMBL1006081 | 0.93 | GSR (0.47) | OTCNOS1NOS2NOS3DDAH1 | |
| SCHEMBL14423587 | 0.93 | GSR (0.47) | OTCNOS1NOS2NOS3DDAH1 | |
| SCHEMBL4393876 | 0.88 | PMP22 (0.43) | OTCNOS1NOS2NOS3GSR | |
| SCHEMBL29533865 | 0.88 | PMP22 (0.43) | OTCNOS1NOS2NOS3GSR | |
| Hydrochloric Acid SCHEMBL30271216 | 0.85 | OTC (0.49) | OTCNOS1NOS2NOS3DDAH1 | |
| SCHEMBL19608041 | 0.85 | DPP7 (0.41) | OTCNOS1NOS2NOS3DDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0651741-A1 | N?G -MONOMETHYL-L-ARGININE HYDROCHLORIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF SEPTIC SHOCK. | WELLCOME FOUND (GB) | 1995-05-10 | — | — | EP | claimed |
| WO-1994002453-A1 | NG-MONOMETHYL-L-ARGININE HYDROCHLORIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF SEPTIC SHOCK | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-02-03 | — | — | WO | claimed |
| US-9533056-B2 | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs | ASCENDIS PHARMA AS (DK) | 2017-01-03 | — | — | US | disclosed |
| EP-2525830-B1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2016-05-11 | — | — | EP | disclosed |
| US-20150202317-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2015-07-23 | — | — | US | disclosed |
| US-9062094-B2 | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs | ASCENDIS PHARMA AS (DK) | 2015-06-23 | — | — | US | disclosed |
| US-8748177-B2 | Compositions for proliferation of cells and related methods | THE HOSPITAL FOR SICK CHILDREN (CA) | 2014-06-10 | — | — | US | disclosed |
| US-8680270-B2 | Metallo-oxidoreductase inhibitors using metal binding moieties in combination with targeting moieties | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| EP-2086546-B1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS INC (US) | 2013-07-10 | — | — | EP | disclosed |
| US-20130053301-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-28 | — | — | US | disclosed |
| US-20110301105-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2011-12-08 | — | — | US | disclosed |
| US-5883130-A | Ng-monomethyl-l-arginine hydrochloride derivatives and their use in the treatment of septic shock | GLAXO WELLCOME INC. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5856565-A | Ng-monomethyl-l-argine hydrochloride derivatives and their use in the treatment of septic shock | GLAXO WELLCOME, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5767312-A | NG -monomethyl-L-arginine hydrochloride derivatives and their use in the treatment of septic shock | GLAXO WELLCOME, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| WO-1997030972-A1 | PROCESS FOR THE PREPARATION OF NG-MONOMETHYL-L-ARGININE HYDROCHLORIDE | GLAXO GROUP LIMITED (GB) | 1997-08-28 | — | — | WO | disclosed |
| EP-0651741-B1 | NG-MONOMETHYL-L-ARGININE HYDROCHLORIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | WELLCOME FOUND (GB) | 1997-01-29 | — | — | EP | disclosed |
| EP-0651741-B1 | NG-MONOMETHYL-L-ARGININE HYDROCHLORIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | WELLCOME FOUND (GB) | 1997-01-29 | — | — | EP | disclosed |
| EP-0651741-A1 | N?G -MONOMETHYL-L-ARGININE HYDROCHLORIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF SEPTIC SHOCK. | WELLCOME FOUND (GB) | 1995-05-10 | — | — | EP | disclosed |
| CN-1087624-A | Arginine derivative | WELLCOME FOUND (GB) | 1994-06-08 | — | — | CN | disclosed |
| WO-1994002453-A1 | NG-MONOMETHYL-L-ARGININE HYDROCHLORIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF SEPTIC SHOCK | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202317-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | DNPEP, PEPD, DAO | NOS1 1941/4885NOS2 1649/4885NOS3 1784/4885 |
| US-20130053301-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | DNPEP, PEPD, DAO | NOS1 1941/4885NOS2 1649/4885NOS3 1784/4885 |
| US-20110301105-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | MKI67, KRT18, PROX1 | NOS1 3060/4885NOS2 3344/4885NOS3 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.